Dr. William H. Geerts

• 
  www.chestnet.org/CHEST/program/symposia.php - [Cached Version]
  Published on: 8/26/2008    Last Visited: 8/26/2008  

  William H. Geerts, MD, FCCPProgram Chair
  ...
  Will the heparins and coumadins be entirely replaced by new therapies?

• 
  www.western-star.com/health/content/shared-auto/healthn - [Cached Version]
  Published on: 6/25/2008    Last Visited: 6/25/2008  

  "It was superior to low molecular weight heparin, one of the two most common prophylaxis modalities in the United States," said Dr. William Geerts, a professor of medicine at the University of Toronto, and a member of a team that tested rivaroxaban after hip replacement surgery.
  ...
  It already has competition from another anti-clotting drug known as dabigatran, which the pharmaceutical company Boehringer Ingelheim has permission to market in Europe and has approval to start marketing in Canada later this month, Geerts said.
  ...
  Both new anti-clotting pills will be an improvement for many people now taking Coumadin, Geerts said.Because of the frequent testing required for Coumadin, many people who are told to take the medication don't follow instructions, he said."This will likely translate to a larger proportion of people who should be on prophylaxis actually getting it," he said.
  
  But the fact that frequent tests aren't required for the new anti-clotting agents is a challenge to physicians, Geerts said.Lab tests are proof-positive that someone is taking their medicine, he said."As physicians, we have to think of new strategies to make sure people are compliant," he added.

• 
  www.theglobeandmail.com/servlet/story/RTGAM.20080402.wc - [Cached Version]
  Published on: 4/2/2008    Last Visited: 4/3/2008  

  If those patients were provided with prophylactic blood thinners, most deaths could be prevented, according to Bill Geerts, a thrombosis specialist at the Sunnybrook Health Sciences Centre in Toronto.Those figures, he said, are extrapolations based on data from the United States.
  
  'It's a bit embarrassing to have not fixed this problem by now,' Dr. Geerts said in a telephone interview. 'The evidence has been pretty compelling for a long, long time.'
  ...
  According to Dr. Geerts, nearly all patients in hospital are at risk for blood clots and most hospitalized patients should receive the blood thinner as a preventive measure.
  
  Those patients include most who undergo major general surgery, orthopedic surgery, neurosurgery and gynecological surgery, such as a hysterectomy.As well, most hospitalized medical patients and most or all intensive-care unit patients should receive it, he said.
  
  Dr. Geerts said there are many reasons why blood thinners are not routinely provided as a preventive measure in the recommended doses.Doctors and other staff may not always appreciate a patient's risk factors.
  
  But the main reason, he said, is that hospitals don't have a system in place to ensure doctors don't forget to order them.
  
  Across Canada, more than two-thirds of acutely ill medical patients, half of all patients undergoing major general surgery and more than 20 per cent of hip fracture surgery patients do not receive the prophylactic anticoagulants, he said.

• 
  cme.medicine.dal.ca/Geerts.htm - [Cached Version]
  Published on: 10/13/2008    Last Visited: 5/12/2008  

  Bill Geerts is a Professor of Medicine at the University of Toronto.He is also a consultant in clinical thromboembolism and Director of the Thromboembolism Program at Sunnybrook Health Sciences Centre in Toronto.
  
  His clinical practice is largely confined to venous thromboembolism and his research spans the areas of diagnosis, treatment, and prevention of thromboembolic disease.His current research interests include knowledge translation in the area of thrombosis prevention and treatment.
  
  For the past 10 years, he has been the chair of the Prevention of Thromboembolism chapter for the American College of Chest Physicians Consensus Guidelines on Antithrombotic Therapy.

• 
  www.ota.org/members_only/articles.cfm - [Cached Version]
  Published on: 10/13/2008    Last Visited: 8/25/2008  

  Author: William H. Geerts, MD, FCCP; Graham F. Pineo, MD; John A. Heit, MD; David Bergqvist, MD, PhD; Michael R. Lassen, MD; Clifford W. Colwell, MD; and Joel G. Ray, MD, MSc

• 
  www.cardiologyassociates.com/handler.cfm?event=newsfeed - [Cached Version]
  Published on: 6/25/2008    Last Visited: 6/28/2008  

  "It was superior to low molecular weight heparin, one of the two most common prophylaxis modalities in the United States," said Dr. William Geerts, a professor of medicine at the University of Toronto, and a member of a team that tested rivaroxaban after hip replacement surgery.
  ...
  It already has competition from another anti-clotting drug known as dabigatran, which the pharmaceutical company Boehringer Ingelheim has permission to market in Europe and has approval to start marketing in Canada later this month, Geerts said.
  ...
  Both new anti-clotting pills will be an improvement for many people now taking Coumadin, Geerts said.Because of the frequent testing required for Coumadin, many people who are told to take the medication don't follow instructions, he said."This will likely translate to a larger proportion of people who should be on prophylaxis actually getting it," he said.
  
  But the fact that frequent tests aren't required for the new anti-clotting agents is a challenge to physicians, Geerts said.Lab tests are proof-positive that someone is taking their medicine, he said."As physicians, we have to think of new strategies to make sure people are compliant," he added.
  
  More information
  
  Learn more about anticoagulant drugs from the American Heart Association.
  
  SOURCES: William Geerts, M.D., professor, medicine, University of Toronto; Richard C. Becker, M.D., professor, medicine, Duke University Medical Center, Durham, N.C.; June 25, 2008, The Lancet, online; June 26, 2008, New England Journal of Medicine

• 
  oldwhatmp3.herhangout.com/2008/06/28/percent-of-those-w - [Cached Version]
  Published on: 1/1/2008    Last Visited: 6/29/2008  

  William Geerts, a professor of medicine at the University of Toronto, and a member of a team that tested rivaroxaban after hip replacement surgery.
  ...
  But the fact that frequent tests aren't required for the new anti clotting agents is a challenge to physicians, Geerts said.As physicians, we have to think of new strategies to make sure people are compliant, he added.Next Article Alzheimer's Drug May Help Preemies raquo.Ask Our Health Experts a Question.

• 
  www.baptistnortheast.com/news/healthscout/?id=616849 - [Cached Version]
  Published on: 10/13/2008    Last Visited: 6/27/2008  

  "It was superior to low molecular weight heparin, one of the two most common prophylaxis modalities in the United States," said Dr. William Geerts, a professor of medicine at the University of Toronto, and a member of a team that tested rivaroxaban after hip replacement surgery.
  ...
  It already has competition from another anti-clotting drug known as dabigatran, which the pharmaceutical company Boehringer Ingelheim has permission to market in Europe and has approval to start marketing in Canada later this month, Geerts said.
  ...
  Both new anti-clotting pills will be an improvement for many people now taking Coumadin, Geerts said.Because of the frequent testing required for Coumadin, many people who are told to take the medication don't follow instructions, he said."This will likely translate to a larger proportion of people who should be on prophylaxis actually getting it," he said.
  
  But the fact that frequent tests aren't required for the new anti-clotting agents is a challenge to physicians, Geerts said.Lab tests are proof-positive that someone is taking their medicine, he said."As physicians, we have to think of new strategies to make sure people are compliant," he added.
  ...
  SOURCES: William Geerts, M.D., professor, medicine, University of Toronto; Richard C. Becker, M.D., professor, medicine, Duke University Medical Center, Durham, N.C.; June 25, 2008, The Lancet, online; June 26, 2008, New England Journal of Medicine

• 
  www.cshpontario.ca/web/la/en/pa/91DAAB323E0144C7BE5A525 - [Cached Version]
  Published on: 10/25/2007    Last Visited: 10/27/2007  

  Dr. William Geerts, MD, FRCPC, FCCPDirector of Thromboembolism Program, Sunnybrook Health Sciences Centre;Professor of Medicine, University of Toronto

• 
  www.stratishealth.org/index.php?src=events&srctype=prof - [Cached Version]
  Published on: 1/23/2007    Last Visited: 3/23/2007  

  Bill Geerts, MD, FRCPC, FCCP, University of Toronto

Page:  1 2 3 4